Transaction DateRecipientSharesTypePriceValue
4th January 2021Jonathan Young2,960Open or private sale$25.27$74,799.20
4th January 2021Jonathan Young100Open or private sale$26.00$2,600.00
28th December 2020Andrew Cheng7,480Exercise of derivative$0.62$4,637.60
21st December 2020Andrew Cheng10,500Exercise of derivative$0.62$6,510.00
15th December 2020Andrew Cheng2,500Bona fide gift$0.00
11th December 2020Andrew Cheng50Bona fide gift$0.00
24th November 2020Tree Partners Iv, L.P. Apple375,000Open or private purchase$39.00$14,625,000.00
24th November 2020Seth Loring Harrison375,000Open or private purchase$39.00$14,625,000.00
23rd November 2020G. Walmsley Graham1,183,114Conversion of derivative$0.00
23rd November 2020G. Walmsley Graham1,400,761Conversion of derivative$0.00
Akero Therapeutics
Akero Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Ticker: AKRO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1744659
Employees: 13
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags